Holen Sie sich die Stockscreener-App
166.95
0.93%
-1.57
Handel nachbörslich:
166.72
-0.23
-0.14%
Schlusskurs vom Vortag:
$168.52
Offen:
$166.58
24-Stunden-Volumen:
822.84K
Relative Volume:
0.86
Marktkapitalisierung:
$9.80B
Einnahmen:
$551.35M
Nettoeinkommen (Verlust:
$-189.33M
KGV:
-50.72
EPS:
-3.2916
Netto-Cashflow:
$-35.09M
1W Leistung:
+8.71%
1M Leistung:
+19.45%
6M Leistung:
+39.85%
1J Leistung:
+93.92%
1-Tages-Spanne:
$165.37
$171.54
1-Wochen-Bereich:
$145.78
$184.00
52-Wochen-Spanne:
$73.16
$184.00
Glaukos Corp Stock (GKOS) Company Profile
Firmenname
Glaukos Corp
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
166.87 | 8.92B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corp Aktie (GKOS) Neueste Nachrichten
Stifel reiterates Glaukos stock rating on Epioxa demand strength By Investing.com - Investing.com Canada
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt - BioSpace
Glaukos Corporation Advances PRESERFLO MicroShunt Study - GuruFocus
Glaukos Completes Enrollment for Glaucoma Implant Study - Orange County Business Journal
Glaukos Corp Revenue Breakdown – BX:GKOS - TradingView
Glaukos (GKOS) Completes Patient Enrollment for Groundbreaking G - GuruFocus
Glaukos completes enrollment in glaucoma device pivotal study - Investing.com
Glaukos completes enrollment with at least 110 glaucoma patients - Stock Titan
Glaukos Corp (GKOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Glaukos Corp (GKOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
GKOS|Glaukos Corp|Price:148.632|Chg%:-4.947 - TradingKey
Glaukos Corp (GKOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Glaukos Corp (GKOS) Balance Sheet - TradingKey
Glaukos Corp (GKOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GKOS|Glaukos Corp|Price:150.479|Chg%:-3.101 - TradingKey
Glaukos Corp (GKOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Glaukos Corp (NYSE: GKOS) CFO trades 10,000 shares under Rule 10b5-1 plan - Stock Titan
GKOS Maintains by Stifel -- Price Target Raised to $175 - GuruFocus
Stifel raises Glaukos stock price target to $175 on iDose outlook - Investing.com Nigeria
Stifel raises Glaukos stock price target to $175 on iDose outlook By Investing.com - Investing.com South Africa
GLAUKOS CORP : TRUIST SECURITIES RAISES TARGET PRICE TO $180 FROM $160 - Bitget
GKOS Maintained by Truist Securities -- Price Target Raised to $180 - GuruFocus
Form 144 GLAUKOS Corp For: 16 July By Investing.com - Investing.com Canada
Alex R. Thurman to sell 10,000 Glaukos (GKOS) shares under Form 144 - Stock Titan
Glaukos Glaucoma Tech Trade Secrets Suit Survives Dismissal Bids - Bloomberg Law News
Glaukos Corp stock hits 52-week high at 156.7 USD By Investing.com - Investing.com Nigeria
Midday Stock Roundup: Western Digital Falls, Resumes Merger Discussions - Orange County Business Journal
Glaukos Corp stock hits 52-week high at 156.7 USD - Investing.com
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now? - The Motley Fool
Glaukos SVP & CFO Alex Thurman sells $1.55m in common stock - Investing.com UK
Glaukos SVP & CFO Alex Thurman sells $1.55m in common stock By Investing.com - Investing.com India
Form 4 Glaukos Corp For: 13 July By Investing.com - Investing.com Australia
Glaukos Corp (NYSE: GKOS) CFO sells 10,000 shares, exercises options under 10b5-1 plan - Stock Titan
Price to sales forward of Glaukos Corp – XETR:6GJ - TradingView
Form 144 GLAUKOS Corp For: 9 July By Investing.com - Investing.com Nigeria
Form 144 GLAUKOS Corp For: 9 July - Investing.com UK
Glaukos (GKOS) Form 144 shows 10,000-share sale, option exercise - Stock Titan
Glaukos chief development officer Navratil sells $99,566 stock By Investing.com - Investing.com South Africa
Glaukos Corp CFO Alex Thurman sells $1.5m in shares By Investing.com - Investing.com India
Glaukos Corp CFO Alex Thurman sells $1.5m in shares - Investing.com
Form 4 Glaukos Corp For: 8 July By Investing.com - Investing.com Nigeria
Glaukos (GKOS) CFO executes pre-planned share sale and option exercise - Stock Titan
Glaukos chief development officer Navratil sells $99,566 stock - Investing.com
Form 4 Glaukos Corp For: 8 July - Investing.com UK
Finanzdaten der Glaukos Corp-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Glaukos Corp-Aktie (GKOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER |
Jul 16 '26 |
Sale |
160.00 |
10,000 |
1,600,000 |
43,906 |
1.04%
11.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):